drugset / Trial / NCT02039700

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

NCT02039700

Phase 1 Completed 10 enrolled Ardea Biosciences, Inc.
NaSingle-groupOpen-labelBasic science

Summary

This study will assess the absolute bioavailability of a single oral dose of lesinurad and evaluate the pharmacokinetic (PK) parameters of lesinurad and \[14C\]lesinurad in healthy adult male subjects.

Timeline

Start
2014-01
Primary completion
2014-02
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lesinurad Small molecule 100 ug Oral
Subject Lesinurad Small molecule 400 mg Oral

Indications

No indication recorded.